No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMLX240517C3000
- 0.03
- +0.02+200.00%
15min DelayClose May 16 15:57 ET
0.03High0.02Low
0.02Open0.01Pre Close2 Volume1.98K Open Interest3.00Strike Price5.00Turnover689.81%IV65.57%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.03Time Value100Contract SizeAmericanOptions Type0.1106Delta0.2922Gamma61.00Leverage Ratio-0.0622Theta0.0000Rho6.75Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
Amylyx Pharmaceuticals(AMLX.US) Director Buys US$9,436.03 in Common Stock
$Amylyx Pharmaceuticals(AMLX.US)$ Director Quimi Daphne purchased 5,000 shares of common stock on May 14, 15, 2024 at an average price of $1.8872 for a total value of $9,436.03.Source: Announcement Wh
Amylyx Pharmaceuticals(AMLX.US) Officer Sells US$19,654.35 in Common Stock
$Amylyx Pharmaceuticals(AMLX.US)$ Officer Mazzariello Gina sold 10,455 shares of common stock on May 15, 2024 at an average price of $1.8799 for a total value of $19,654.35.Source: Announcement What i
Amylyx Pharmaceuticals Is Maintained at Neutral by Mizuho
Amylyx Pharmaceuticals Is Maintained at Neutral by Mizuho
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Wave Life Sciences (WVE) and GoodRx Holdings (GDRX)
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), IN8bio (INAB) and Privia Health Group (PRVA)
Express News | Amylyx Pharmaceuticals Inc : Mizuho Cuts Target Price to $3 From $4
Comments
$Amylyx Pharmaceuticals(AMLX.US$ flat and searching for the new low. How much lower can it be 😂
$Amylyx Pharmaceuticals(AMLX.US$ Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
1
$Amylyx Pharmaceuticals(AMLX.US$
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
1
Analysts predict a revenue drop and higher losses per share for Amylyx Pharmaceuticals, indicating slower sales growth than the market, potentially causing market wariness.
1
Read more